Clinical Data

Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline

BioSpace

William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results "another derisking step" for the company's immunol

Clinical Data Immunology & Inflammation Read full story

pharminent March 30, 2026 (Last updated: March 30, 2026)

BioSpace

William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunol

Clinical Data Immunology & Inflammation Read full story

Related Stories

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise